Skip to main content
Clinical Trials/EUCTR2021-001453-31-DK
EUCTR2021-001453-31-DK
Active, not recruiting
Phase 1

Automated pupillometry and NIRS-EEG to detect signatures ofconsciousness in acute brain injury after apomorphine andmethylphenidate stimulation: A placebo-controlled, randomized, cross-overstudy

Copenhagen University Hospital Rigshospitalet0 sites41 target enrollmentMarch 22, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
We investigate the possible effects of commercially availableapomorphine and methylphenidate on signatures of consciousness inpatients admitted to the ICU with acute disorder of consciousness, usingautomated pupillometry and NIRS-EEG.
Sponsor
Copenhagen University Hospital Rigshospitalet
Enrollment
41
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 22, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Copenhagen University Hospital Rigshospitalet

Eligibility Criteria

Inclusion Criteria

  • Age \= 18 years.
  • Fluent in Danish or English language
  • Patients with severe acute traumatic or non\-traumatic brain injury in a
  • state of vegetative state/unresponsive wakefulness syndrome or
  • minimal consciousness state according to FOUR and SECONDs.
  • Written informed consent for trial participation from next\-of\-kin.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 20

Exclusion Criteria

  • Recovery of the ability to follow commands clinically prior to
  • enrollment.
  • Pre\-existing disorder of consciousness before the onset of brain injury.
  • Pre\-existing mental or physical impairments.
  • Deafness, blindness or bilateral eye surgery before the onset of brain
  • Ongoing use of dopamine agonists or antagonists within 6 half\-lives of
  • Ongoing or previous use of psychoactive or psychotropic substances 2
  • weeks prior examination or within 6 half\-lives of the drug.
  • Clinically unstable patients requiring immediate neurological, medical
  • or surgical management.

Outcomes

Primary Outcomes

Not specified

Similar Trials